α-Synuclein Biomarkers for Parkinson's Disease

Area of Science:

• Neurology
• Biomarker Research
• Neurodegenerative Diseases

Background:

• Alpha-synuclein (α-syn) is a key protein implicated in Parkinson's disease (PD) and other synucleinopathies.
• Biomarkers for α-syn show diagnostic potential for PD, even in early prodromal stages like REM sleep behavior disorder and hyposmia.
• Understanding α-syn pathophysiology is vital for both idiopathic and genetic forms of PD.

Purpose of the Study:

• To review the current status of α-syn biomarkers for Parkinson's disease.
• To highlight the potential clinical and research applications of α-syn detection.
• To identify areas requiring further investigation for biomarker validation.

Main Methods:

• Review of existing literature on α-syn biomarker studies.
• Discussion of prevalent detection methods, including immunohistochemistry and α-syn seed amplification assays.
• Analysis of α-syn detectability across various tissues and biofluids.

Main Results:

• α-syn biomarkers demonstrate high diagnostic sensitivity and specificity for PD.
• Detection is feasible in multiple biological samples, each with unique advantages and limitations.
• Lack of standardized detection methods currently hinders interlaboratory validation.

Conclusions:

• α-syn biomarkers hold significant promise for the diagnosis and management of PD.
• Standardization and verification of assays are essential for clinical integration.
• Further research is needed to fully realize the potential of α-syn biomarkers in PD and related disorders.